Guilford restructuring
Executive Summary
Guilford plans to reduce its workforce by approximately 25% to 220 employees following suspension of several R&D programs and a decision to focus on more advanced clinical projects. The company will concentrate on the anesthetic agent Aquavan (propofol pro-drug) and the Parkinson's disease agent GPI-1485, both in Phase II studies. Guilford expects to take a restructuring charge of up to $1.5 mil. in the third quarter. The program is expected to result in estimated annualized savings of approximately $10 mil.-$12 mil., beginning in 2003...